Eisai to Acquire Global Rights to Four Oncology-Related Products from Ligand Pharmaceuticals (LGND)
More News related to LGND
- Morning Movers 11/06: ACLS, CVM, ZIOP, LPSN, CABL, ZGEN Higher; NHWK, GOK, CROX, CVI, RAIL, CSTR Lower
- Ligand Pharma (LGND) Posts Q3 Loss of 3c, Tops by 1c; Guides
- Ligand Pharmaceuticals Announces Third Quarter Results
- Ligand's JAK3 Research Collaboration Extended by Pfizer
- Ligand Updates License Agreement with Exelixis
More News related to Mergers and Acquisitions
- Motorola (MOT) is going to seek buyers for its home and networks division, which is worth roughly $4.5 billion - WSJ
- Logitech (LOGI) Acquires LifeSize Comm for $405M
- IESI-BFC (BIN) And Waste Services (WSII) Announce Merger Agreement
- Smith & Nephew (SNN) to Acquire NUCRYST Pharma. (NCST) Acticoat Business fpr $21M ; Enters into Amalgamation with Westaim Corp.
- Stryker (SYK) Announces Two Acquisitions
Eisai has announced that it signed a product acquisition agreement with Ligand Pharmaceuticals (Nasdaq: LGND) for exclusive global rights for their four oncology-related products, ONTAK, Targretin capsules, Targretin gel 1% and Panretin gel 0.1%.
The transaction is subject to governmental approvals and is expected to close after certain preparation period. Eisai will pay U.S. $205 million for the acquisition, and offer Ligand personnel employment by Eisai Inc
Related Categories
Mergers and AcquisitionsStocks Mentioned
+0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
